Announcements Trials
Browse Landscape

Phase

Phase 2 1

Status

Recruiting 2Terminated 1Completed 1

Sponsor Class

OTHER 1

Study Type

Interventional 1

Sponsor

Cancer Type

Plasma cell 1

Conditions

Multiple Myeloma 10Burkitt Lymphoma 5Precursor Cell Lymphoblastic Leukemia-Lymphoma 3Vomiting 2Precursor T-Cell Lymphoblastic Leukemia-Lymphoma 2Nausea 2Smoldering Multiple Myeloma 1Renal Insufficiency 1Prostatic Neoplasms 1Plasmacytoma 1Ovarian Neoplasms 1Myelodysplastic Syndromes 1Lymphoma, Non-Hodgkin 1Lymphoma, Large B-Cell, Diffuse 1Lymphoma, Follicular 1Leukemia, Myelomonocytic, Chronic 1Leukemia, Myeloid, Acute 1Leukemia, Myelogenous, Chronic, BCR-ABL Positive 1Hematologic Neoplasms 1Gastrointestinal Neoplasms 1Fallopian Tube Neoplasms 1Brenner Tumor 1Blast Crisis 1

Interventions

Dexamethasone 2Calcium Dobesilate 2Bortezomib 2pomalidomide 1ibrutinib 1dexamethasone acetate 1dexamethasone 21-phosphate 1auricularum 1atezolizumab 1Transplantation, Autologous 1Melphalan 1Lenalidomide 1Gene Expression Profiling 1Fatty Acids, Omega-3 1Biopsy 1

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
Terminated × Smoldering Multiple Myeloma × auricularum × Clear all
NCT05288062 2025-08-20

Immunomodulatory Drugs (Lenalidomide With or Without Pomalidomide) in Combination With a Corticosteroid Drug (Dexamethasone) for the Treatment of Multiple Myeloma

Mayo Clinic

Phase 2 Terminated
17 enrolled 9 charts
Plasma cell

Smoldering Multiple Myeloma, Multiple Myeloma

Data powered by HemOnc (CC BY 4.0) Colophon âš¡